In addition to the disappointing responses of these cancers to such treatments, patients undergoing these therapies experienced serious adverse effects that, with the advent of targeted therapies like mTOR and VEGFR inhibitors, led to the near-abandonment of IFNα and IL-2 as mainstream RCC therapies [20, 25, 26]. This evidence concerns the gene MTOR and renal cell carcinoma.